Aprotinin

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Trasylol; Germany: Trasylol; Greece: Trasylol; Hungary: Gordox, Trasylol; Ireland: Trasylol; Luxembourg: Iniprol, Trasylol; Malta: Trasylol; Poland: Traskolan, Trasylol; Sweden: Trasylol.

North America

Canada: Trasylol; USA: Trasylol.

Latin America

Brazil: Trasylol.

Asia

Japan: Trasylol.

Drug combinations

Aprotinin and Protein C Concentrate (Human)

Aprotinin, Calcium Chloride, Fibrinogen, and Thrombin

Aprotinin, Collagen, Fibrinogen, and Thrombin

Aprotinin, Calcium Chloride, Factor XIII, Fibrinogen, Fibronectin, Plasminogen, Proteins, and Thrombin

Chemistry

Aprotinin: C~284~H~432~N~84~O~79~S~7~. Mw: 6511.44. (1) Trypsin inhibitor, pancreatic basic; (2) L-Arginyl-L-prolyl-L-aspartyl-L-phenylalanyl-L-cysteinyl-L-leucyl-L-glutamyl-L-prolyl-L-prolyl-L-tyrosyl-L-threonylglycyl-L-prolyl-L-cysteinyl-L-lysyl-L-alanyl-L-arginyl-L-isoleucyl-L-isoleucyl-L-arginyl-L-tyrosyl-L-phenylalanyl-L-tyrosyl-L-asparaginyl-L-alanyl-L-lysyl-L-alanylglycyl-L-leucyl-L-cysteinyl-L-glutaminyl-L-threonyl-L-phenylalanyl-L-valyl-L-tyrosylglycylglycyl-L-cysteinyl-L-arginyl-L-alanyl-L-lysyl-L-arginyl-L-asparaginyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-seryl-L-alanyl-L-glutamyl-L-aspartyl-L-cysteinyl-L-methionyl-L-arginyl-L-threonyl-L-cysteinylglycylglycyl-L-alanine cyclic (5→55), (14→38), (30→51) tris(disulfide). CAS-9087-70-1; CAS-12407-79-3 (ox pancreas basic); CAS-11061-94-2 (ox pancreas basic reduced)(1968).

Pharmacologic Category

Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02AB01).

Mechanism of action

Attenuates coagulation, fibrinolytic and inflammatory pathways by interfering with the chemical mediators (thrombin, plasmin, kallikrein) and protects platelet-expressed glycoproteins from mechanical shear forces.

Therapeutic use

Prevention of perioperative blood loss during coronary artery bypass graft surgery.

Pregnancy and lactiation implications

Teratogenic effects were not observed in animal studies. Use with caution during pregnancy or lactation.

Unlabeled use

Contraindications

Hypersensitivity to aprotinin or any component of the formulation. Known or suspected exposure within the past 12 months.

Warnings and precautions

High rate of mortality and of heart failure in observational studies. Anaphylactic, hypersensitivity reactions are possible (hypotension is the most frequently reported sign). May cause serious kidney damage (renal dysfunction may occur).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart